| Name | Title | Contact Details |
|---|
MDSave is an online marketplace for customers to shop and compare medical services the same way they shop for everything else. Patients can select their provider based on quality and clear pricing.
We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be circulating in a local area or within a user`s school. Kinsa is ready to help whole communities better track, treat, and stop the spread of illness. But we know we`ll only do it if our products delight users from their first touch. It’s with this in mind that we developed the Kinsa Smart Thermometer.
St. Cloud Regional Medical Center is situated in the heart of St. Cloud, Florida. The modern 84-bed, acute care facility offers a comprehensive medical support system for both inpatient and outpatient needs. St. Cloud Regional Medical Center has always been committed to offering the highest level of compassionate care. Our physicians and staff are dedicated to delivering this care in an environment that is efficient and comfortable. St. Cloud Regional Medical Center staff is comprised of physicians ranging from family practice, internal medicine and general surgery. These professionals are highly skilled in their fields and are at the core of the great healthcare that we deliver to the residents of Osceola County.
Xymogen is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.